Hematologic Malignancy
Chronic Eosinophilic Leukemia, Not Otherwise Specified
CI-CAN-00002361CELExplore in graph →
Hematologic2 active trials2 approved drugs
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002361CELExplore in graph →
Clinical trials
25 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER | 1 |
| Feb 3, 2021 |
| clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT00381550 | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 6, 2015 | clinicaltrials |
| NCT00787384 | Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes(NILG-HES1-03) | completed | Phase 2 | 25 | Northern Italy Leukemia GroupOTHER | 1 | Dec 29, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Apr 15, 2026source: clinicaltrials